Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline

Exegenesis Bio Inc., a gene therapy developer founded in 2019, filed for a listing on the Hong Kong Stock Exchange (HKEX), seeking to raise approximately USD 150‑200 million to advance its AI‑enhanced pipeline targeting spinal muscular atrophy (SMA) and ocular diseases. The company leverages proprietary platforms AAVarta and SODA to develop next‑generation gene therapies.

IPO Milestone

Technology Platforms

AAVarta – AI-Assisted AAV Capsid Evolution

• Function: Proprietary AAV capsid discovery platform using machine learning to engineer novel serotypes with enhanced tissue tropism and reduced immunogenicity
• Innovation: In silico prediction of capsid variants followed by high‑throughput in vivo screening; reduces discovery timeline from 36 months to 12 months

SODA – Silencing Oligonucleotide Design Approach

• Function: AI‑driven design of antisense oligonucleotides (ASOs) and siRNAs for target knockdown
• Advantage: Optimizes chemical modifications, delivery vectors, and off‑target profiling simultaneously

Clinical Pipeline

Market Opportunity

Financial & Strategic Positioning

• Valuation: Pre‑money estimated at USD 500‑600 million based on comparable AI‑gene therapy companies
• Revenue Model: Near‑term partnership revenues (platform licensing); long‑term product sales and milestones
• Investor Base: Viva Biotech (incubator) remains largest shareholder; new investors include Hong Kong‑based family offices and biotech crossover funds
• Manufacturing: In‑house GMP facility in Hangzhou (2,000L scale) for AAV production; capacity for clinical supply through Phase II

Competitive Advantages

• AAVarta Platform: Novel capsids show 5‑fold higher retinal transduction and 3‑fold lower liver sequestration vs. AAV2/AAV8 in preclinical models
• Integrated AI: SODA platform reduces oligonucleotide design cycles from 6 months to 8 weeks
• Cost Efficiency: In‑house manufacturing reduces COGS by 40% vs. CDMO model
• Diversification: Dual platform (gene therapy + oligonucleotide) mitigates AAV immunogenicity risks

Forward‑Looking Statements
This brief contains forward‑looking statements regarding Exegenesis Bio’s IPO timeline, valuation, and pipeline advancement. Actual results may differ due to market conditions, regulatory review timelines, and competitive dynamics in gene therapy.-Fineline Info & Tech